The Effect of Exacerbation History on Outcomes in the IMPACT Trial

David M.G. Halpin MD,¹ Mark T. Dransfield MD,² MeiLan K. Han MD MS,³ C. Elaine Jones PhD,⁴ Sally Kilbride MSc,⁵ Peter Lange MD,⁶,⁷ David A. Lipson MD,⁸,⁹ David A. Lomas MD PhD,¹⁰ Fernando J. Martinez MD MS,¹¹ Steve Pascoe MBBS MS,¹¹* Dave Singh MD,¹² Robert Wise MD,¹³ Gerard J. Criner MD¹⁴

¹University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK; ²Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA; ³University of Michigan, Pulmonary & Critical Care, Ann Arbor, Michigan, USA; ⁴GlaxoSmithKline, Research Triangle Park, NC, USA; ⁵GlaxoSmithKline, Stockley Park, UK; ⁶Medical Department, Herlev and Gentofte Hospital, Herlev, Denmark; ⁷University of Copenhagen, Copenhagen, Denmark; ⁸GlaxoSmithKline, Collegeville, PA, USA; ⁹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; ¹⁰UCL Respiratory, University College London, London, UK; ¹¹New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, USA; ¹²University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Hospitals Trust, Manchester, UK; ¹³Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, MD, USA; ¹⁴Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA

*Affiliation at the time of the study; current affiliation: Sanofi, Philadelphia, PA, USA.

Corresponding author:
David M.G. Halpin MD
University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, EX1 2LU, UK
Email: d.halpin@nhs.net
Tel: +44 (0)1392 402133
Target journal: ERJ
Word count: 2999 (max. 3000)
Tables/Figures: 2 tables/6 figures (max. 8)
Take home message

In COPD patients, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) shows benefits vs FF/VI and UMEC/VI across multiple endpoints irrespective of prior exacerbation history. Exacerbation history and eosinophil counts influenced the comparison between UMEC/VI and FF/VI. Eosinophil counts also influenced the comparison between FF/UMEC/VI and UMEC/VI, albeit to a lesser extent.

@ERSpublications twitter feed summary (230/256 characters)

In patients with COPD, FF/UMEC/VI shows benefits versus FF/VI and UMEC/VI across multiple endpoints irrespective of prior exacerbation history. Exacerbation history and eosinophil counts influenced the comparison between UMEC/VI and FF/VI.

Keywords: COPD, exacerbation history, exacerbation rates, triple therapy, ICS/LABA, LAMA/LABA, eosinophil count
Abstract

IMPACT, a 52-week, randomised, double-blind trial, assessed the efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI or UMEC/VI in patients with symptomatic chronic obstructive pulmonary disease and a history of exacerbations.

Subgroup analyses assessed whether the efficacy of FF/UMEC/VI versus FF/VI or UMEC/VI, and UMEC/VI versus FF/VI, varies according to prior exacerbation history, and the combined effects of exacerbation history and blood eosinophil counts. Three subgroups were defined: single moderate (1 moderate/no severe; n=3056 [30%]), frequent moderate (≥2 moderate/no severe; n=4628 [45%]) and severe (≥1 severe/any moderate; n=2671 [26%]). Endpoints included annual on-treatment moderate/severe exacerbation rate (pre-specified), lung function, and health status (both post hoc).

Moderate/severe exacerbation rates were reduced in the FF/UMEC/VI group versus FF/VI (% reduction [95% confidence interval]: single moderate: 20% [10-29]; frequent moderate: 11% [2-19]; severe: 17% [7-26]) and versus UMEC/VI (single moderate: 18% [5-29]; frequent moderate: 29% [21-37]; severe: 26% [14-35]). Moderate/severe exacerbation rates were reduced in the FF/VI group versus UMEC/VI in the frequent moderate subgroup; a numerical reduction was observed in the severe subgroup (single moderate: 2% [-12-18]; frequent moderate: 21% [11-29]; severe: 11% [-3-22]). Moderate/severe exacerbation rates were lower in the FF/VI group compared with UMEC/VI in patients with higher eosinophil counts. FF/UMEC/VI improved lung function and health status versus both dual therapies irrespective of exacerbation subgroup. UMEC/VI improved lung function versus FF/VI in all subgroups.
Triple therapy was more effective than dual regardless of exacerbation history, consistent with results in the intent-to-treat population. Comparisons between dual therapies were influenced by prior exacerbation history and eosinophil counts.

Funding: GSK (CTT116855/NCT02164513).
INTRODUCTION

Pharmacological treatment of patients with chronic obstructive pulmonary disease (COPD) aims to reduce symptoms, improve health status and reduce exacerbations.[1, 2] The ECLIPSE (NCT00292552) and SPIROMICS (NCT01969344) studies have shown that future exacerbation risk is best predicted by history of prior exacerbations.[3-5] In ECLIPSE, patients with 1 or 2 exacerbations in the previous year had a 2-fold or 5-fold increased risk of exacerbation in the subsequent year, respectively.[4] The 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report recommends assessing exacerbation risk based on patients’ prior 12-month history of exacerbations, with ≥2 moderate or 1 severe exacerbation used to predict those at higher risk.[1, 6]

Analyses from randomised clinical trials in COPD patients with a history of exacerbations have shown that blood eosinophil counts predict inhaled corticosteroids (ICS) effects on exacerbation prevention.[7-10] GOLD recommends blood eosinophils as a biomarker to help guide ICS use, with lower counts (<100 eosinophils/µL) suggesting a low probability of treatment benefit and higher counts (>300 eosinophils/µL) suggesting a high probability.[6]

The Informing the Pathway of COPD Treatment (IMPACT) trial evaluated once-daily single-inhaler triple therapy with an ICS, fluticasone furoate (FF), long-acting muscarinic antagonist (LAMA), umeclidinium (UMEC), and long-acting β2-agonist (LABA), vilanterol (VI), compared with dual therapies FF/VI and UMEC/VI in patients with symptomatic COPD at increased exacerbation risk.[11, 12] The magnitude of benefit of triple therapy and FF/VI in reducing exacerbation rates compared with UMEC/VI increased with higher blood eosinophil counts.[13]

Some analyses have reported the effect of prior exacerbation history on exacerbation outcomes following treatment with LAMA/LABA versus ICS/LABA,[14] or with ICS/LAMA/LABA single-
inhaler triple therapy versus ICS/LABA or LAMA monotherapy.[15-17] However, these studies included a limited number of patients at high risk of exacerbations (≥2 in prior year). Post hoc analyses have also suggested that there is an interaction between prior exacerbation history and blood eosinophil counts on exacerbation outcomes.[18, 19] IMPACT offers the opportunity to evaluate whether pharmacological treatment effects differ in patients with only one moderate compared with several moderate or severe exacerbations in the previous year and to examine the relationship between blood eosinophil counts and pharmacological treatment by exacerbation history in a large group of patients with COPD. In these analyses, we examined whether exacerbation history influenced the relative effect of FF/UMEC/VI compared with FF/VI and UMEC/VI on moderate and severe exacerbations, lung function and health-related quality of life in patients with symptomatic COPD and at risk of exacerbations.

METHODS

Study design

IMPACT (GSK study CTT116855; ClinicalTrials.gov number NCT02164513) was a Phase 3, randomised, double-blind, parallel-group, multicentre trial. The primary objective was to evaluate the effects of once-daily FF/UMEC/VI (100/62.5/25 μg) versus FF/VI (100/25 μg) or UMEC/VI (62.5/25 μg) on the rate of moderate or severe COPD exacerbations over 52 weeks. Each regimen was administered in a single dry-powder inhaler (Ellipta). Details of the study design, including entry criteria and study protocol, have been previously reported.[12] The primary efficacy outcome was on-treatment annual rate of moderate/severe exacerbations. The two co-primary treatment comparisons were FF/UMEC/VI versus UMEC/VI, and FF/UMEC/VI versus FF/VI. Secondary outcomes included time-to-first moderate/severe COPD exacerbation, on-treatment annual rate of severe exacerbation, trough forced expiratory volume in 1 second
(FEV₁), St George’s Respiratory Questionnaire (SGRQ) Total Score and proportion of SGRQ responders (≥4 units decrease in SGRQ Total Score from baseline) at Week 52.

These endpoints were analysed according to patient exacerbation history in the 12 months prior to screening and were classified into three subgroups: single moderate (1 moderate and no severe exacerbation), frequent moderate (≥2 moderate, no severe) and severe (≥1 severe exacerbation regardless of number of moderate).

Throughout the study, COPD exacerbation severity was categorised as mild, moderate or severe. Mild exacerbations were events not treated with corticosteroids or antibiotics, moderate exacerbations required treatment with systemic corticosteroids and/or antibiotics, and severe exacerbations resulted in hospitalisation or death.

Institutional review boards for human studies at each clinical site approved the protocol and written informed consent was obtained from each patient.

**Patients**

Patients enrolled were ≥40 years of age with symptomatic COPD (COPD Assessment Test score ≥10; range 0–40, with higher scores indicating more symptoms; minimal clinically important difference [MCID] 2 units[20]). Patients had to have either a FEV₁ <50% of predicted with ≥1 moderate or severe exacerbations in the prior year, or FEV₁ of 50 to <80% of predicted and ≥2 moderate or ≥1 severe exacerbations in the prior year. Patients continued to take their maintenance medication during a 2-week run-in period before randomisation.

**Statistical analyses**

Analyses were performed on the intent-to-treat population that comprised all randomised patients (N=10,355), excluding those who were randomised in error who did not receive a dose
of study medication (N=12). Patients were randomised in a 2:2:1 ratio to receive FF/UMEC/VI (N=4151), FF/VI (N=4134) or UMEC/VI (N=2070).

The annual rate of on-treatment moderate/severe exacerbations and severe exacerbations was analysed using a generalised linear model assuming a negative binomial distribution with covariates of treatment group, sex, smoking status at screening, geographical region and post-bronchodilator percent predicted FEV1 at screening.

Time-to-first exacerbation endpoints were analysed using a Cox proportional hazards model with the same covariates as the annual rate endpoints.

Change from baseline in trough FEV1 and SGRQ total score were analysed using mixed repeated measures models with covariates of treatment group, smoking status at screening, geographical region, visit, relevant endpoint at baseline, baseline by visit and treatment group by visit interactions.

Proportions of SGRQ responders were analysed using a generalised linear mixed model with a logit link function and covariates of treatment group, smoking status at screening, geographical region, visit, SGRQ total score at baseline, baseline by visit and treatment group by visit interactions.

We used fractional polynomials to model continuous blood eosinophil counts [13] and plotted the selected best-fitting model as continuous eosinophil count versus exacerbation rate in each treatment group for each of the prior exacerbation subgroups. Moderate and severe exacerbation rates on each treatment in each subgroup were also calculated by quintiles of eosinophil counts (<90, 90–<140, 140–<200, 200–<310, ≥310 cells/µL.)
Analyses were performed for each subgroup separately. Analysis of on-treatment moderate/severe exacerbation rates by exacerbation history subgroup was prespecified; all other analyses performed on these subgroups were post hoc.

RESULTS

Patient population

Baseline demographics were similar across the different subgroups (Table 1) and in subgroups by treatment assignment (Supplementary Table 1). There were differences in the severity of airflow obstruction across the three subgroups. The single moderate subgroup had a lower mean FEV\textsubscript{1} predicted and lower mean FEV\textsubscript{1}/forced vital capacity (FVC) ratio than the other two subgroups, reflecting the inclusion criteria (Table 1). More patients in the severe subgroup were on triple therapy at enrolment. There were no meaningful differences in baseline characteristics or prior medication use between treatment arms in each prior exacerbation subgroup.

Association between prior exacerbation history, blood eosinophil count and exacerbation outcomes

There appeared to be a possible association between prior exacerbation history and the number of exacerbations patients experienced during the study. The severe subgroup had a slightly greater proportion of patients having ≥3 on-treatment moderate or severe exacerbations compared with the other subgroups (Figure 1).

The proportion of patients having just one moderate exacerbation during the study was similar across all three exacerbation history subgroups (40–46%) and was not affected by treatment (Table 2). In contrast, over twice as many patients in the severe subgroup experienced an on-treatment severe exacerbation compared with patients in the single moderate or frequent moderate subgroups (20–23% vs 6–10%).
In the frequent moderate subgroup, the proportion of patients who experienced on-treatment severe exacerbations was lower for FF/UMEC/VI and FF/VI (6% and 7%, respectively) versus UMEC/VI (10%) (Table 2).

Single moderate subgroup

In the single moderate subgroup, patients treated with FF/UMEC/VI had a significantly lower annual rate of on-treatment moderate/severe exacerbations versus those treated with FF/VI (rate ratio: 0.80; 95% confidence interval [CI]: 0.71, 0.90) and UMEC/VI (rate ratio: 0.82; 95% CI: 0.71, 0.95). The model estimated annual rate of on-treatment moderate/severe exacerbations was similar in patients treated with UMEC/VI (1.03; 95% CI: 0.92, 1.16) and FF/VI (1.06; 95% CI: 0.97, 1.15) (Figure 2A). Patients treated with FF/UMEC/VI also had a significantly lower risk of a moderate/severe exacerbation compared with those who received FF/VI (hazard ratio [HR]: 0.81; 95% CI: 0.72, 0.91) (Figure 3A). The risk reduction point estimates favoured FF/UMEC/VI over UMEC/VI (HR: 0.92; 95% CI: 0.79, 1.06) and UMEC/VI over FF/VI but were not significant (HR: 0.88; 95% CI: 0.76, 1.02) (Figure 3A).

There were no statistically significant differences in annual rate of on-treatment severe exacerbations with patients treated with FF/UMEC/VI versus those treated with UMEC/VI or FF/VI (Figure 2B). The proportion of patients experiencing a severe exacerbation was 9% for all three treatment arms and there was no difference in the risk when comparing FF/UMEC/VI with FF/VI (HR: 0.99; 95% CI: 0.76, 1.28) or UMEC/VI (HR: 1.00; 95% CI: 0.72, 1.38) (Figure 3B).

When modelled according to blood eosinophil counts, exacerbation rates in the three treatment groups were similar at counts below approximately 200 cells per µL (Figure 4A). Rates were lower in the FF/UMEC/VI treatment group compared with the UMEC/VI treatment group at
higher eosinophil counts: the rates of moderate/severe exacerbations were 0.88 (95% CI 0.73, 1.05) for FF/UMEC/VI and 0.95 (0.74, 1.22) for UMEC/VI at counts 140–<200 cells/µL, 0.76 (0.64, 0.92) for FF/UMEC/VI and 1.03 (0.81, 1.30) for UMEC/VI at 200–<310 cells/µL and 1.08 (0.89, 1.32) for FF/UMEC/VI and 1.21 (0.93, 1.57) for UMEC/VI at counts ≥310 cells/µL (Supplementary Table 2). For FF/VI compared to UMEC/VI, the modelled mean values suggest lower exacerbation rates for patients treated with UMEC/VI at low eosinophil counts, and lower exacerbation rates for those treated with FF/VI at high eosinophil counts, but the confidence intervals were not significant for these numerical trends (Figure 5A).

**Frequent moderate subgroup**

In the frequent moderate subgroup, the annual rate of on-treatment moderate/severe exacerbations was significantly lower for patients receiving FF/UMEC/VI versus FF/VI (rate ratio: 0.89; 95% CI: 0.81, 0.98) or UMEC/VI (rate ratio: 0.71; 95% CI: 0.63, 0.79) (Figure 2A), and the risk of a moderate/severe exacerbation was significantly lower for patients receiving FF/UMEC/VI compared with UMEC/VI (HR: 0.80; 95% CI: 0.72, 0.90) (Figure 3A). The FF/UMEC/VI treatment group also had a lower annual rate of on-treatment severe exacerbations compared with the UMEC/VI group (rate ratio: 0.45; 95% CI: 0.33, 0.61) (Figure 2B). The annual rate and the risk of on-treatment moderate/severe exacerbations was significantly lower in the FF/VI than the UMEC/VI treatment group (rate ratio: 0.79; 95% CI: 0.70, 0.89; HR: 0.87; 95% CI: 0.78, 0.98) and so was the annual rate of severe exacerbations (rate ratio: 0.53; 95% CI: 0.39, 0.75) (Figure 2 and Figure 3A).

Exacerbation rates modelled according to blood eosinophil counts in the three treatment groups were similar at counts below approximately 100 cells per/µL (Figure 4B). Above this level, rates were significantly higher in the UMEC/VI treatment group versus FF/UMEC/VI and FF/VI groups.
(Figure 5B) with rates of moderate/severe exacerbations of 0.85 (95% CI: 0.73, 0.98) for FF/UMEC/VI, 0.93 (0.81, 1.08) for FF/VI and 1.25 (1.04, 1.51) for UMEC/VI at counts 200–<310 cells/µL and 0.87 (0.75, 1.01) for FF/UMEC/VI, 0.91 (0.79, 1.06) for FF/VI and 2.05 (1.70, 2.49) for UMEC/VI at counts ≥310 cells/µL (Supplementary Table 2).

**Severe subgroup**

In the severe subgroup, patients treated with FF/UMEC/VI had a reduced rate and risk of on-treatment moderate/severe exacerbations versus those treated with FF/VI (rate ratio: 0.83; 95% CI: 0.74, 0.93, HR: 0.81; 95% CI: 0.72, 0.91) and UMEC/VI (rate ratio: 0.81; 95% CI: 0.70, 0.93) and also had a reduced rate of on-treatment severe exacerbations versus those treated with FF/VI (rate ratio: 0.88; 95% CI: 0.72, 1.08) and UMEC/VI (rate ratio: 0.69; 95% CI: 0.54, 0.88) (Figure 2 and Figure 3A). The FF/VI treatment group had a greater reduction in the annual rate of severe exacerbations than the UMEC/VI group (rate ratio: 0.78; 95% CI: 0.61, 1.00). The point estimate favoured FF/VI over UMEC/VI for moderate/severe exacerbation rates (rate ratio: 0.89; 95% CI: 0.77, 1.03), but there were no differences observed between patients treated with FF/VI and those treated with UMEC/VI on the time-to-first moderate/severe exacerbation (HR: 1.00; 95% CI: 0.86, 1.14) (Figure 2 and Figure 3A).

Exacerbation rates modelled according to blood eosinophil counts in the three treatment groups were similar at counts below approximately 100 cells per/µL (Figure 4C). Above this level, the FF/UMEC/VI and FF/VI treatment groups had lower rates than the UMEC/VI group (Figure 5C), with rates of moderate or severe exacerbations of 0.89 (95% CI: 0.73, 1.07) for FF/UMEC/VI, 1.35 (1.14, 1.59) for FF/VI and 1.42 (1.11, 1.80) for UMEC/VI at counts 200–<310 cells/µL and 1.20 (1.01, 1.43) for FF/UMEC/VI, 1.20 (1.00, 1.44) for FF/VI and 2.02 (1.59, 2.58) for UMEC/VI at counts ≥310 cells/µL (Supplementary Table 2).
Association between prior exacerbation history and health status

In all subgroups, the mean change from baseline in SGRQ Total Score at Week 52 for the FF/UMEC/VI treatment group was greater than the MCID (4 units)[21], and in each subgroup the improvement in SGRQ Total Score from baseline was greater in the FF/UMEC/VI treatment group (Single: −4.8, Frequent: −6.3, Severe: −4.6), than the FF/VI (Single: −2.4, Frequent: −4.9, Severe: −2.9) and UMEC/VI treatment groups (Single: −3.0, Frequent: −4.5, Severe: −3.0), both of which showed similar effects (Figure 6). The mean changes from baseline in SGRQ Total Score at Week 52 for all treatments were greater in the frequent moderate subgroup than the other subgroups. A larger proportion of patients on FF/UMEC/VI had a 4-unit change in SGRQ Total Score at Week 52 compared with FF/VI or UMEC/VI, regardless of exacerbation history (Supplementary Figure 1).

Association between prior exacerbation history on trough FEV₁ during the study

Mean change from baseline in trough FEV₁ at Week 52 according to exacerbation history is shown in Supplementary Figure 2. In all three subgroups, patients treated with FF/UMEC/VI had a significantly improved trough FEV₁ compared with those treated with FF/VI (by ~100 mL) and UMEC/VI (by 30 to ~70 mL). The UMEC/VI treatment group had a greater improvement in trough FEV₁ than the FF/VI treatment group (by 27–63 mL).

Safety data have been previously published.[11] The safety profile of FF/UMEC/VI was similar to that of FF/VI and UMEC/VI, with no new identified safety signals.[11]

DISCUSSION

These analyses based on prior exacerbation history show that in patients with symptomatic COPD and at risk of exacerbations, triple therapy (FF/UMEC/VI) was superior to dual therapy for preventing exacerbations and improving health status and FEV₁, regardless of exacerbation history.
history. Analysis based on both prior exacerbation history and blood eosinophil counts showed no significant difference in exacerbation rates with triple therapy compared with dual therapy in patients with lower eosinophil counts irrespective of prior exacerbation history. The comparative effects of LAMA/LABA versus ICS/LABA varied according to previous exacerbation history and were different for different outcomes; importantly, the effects of FF/VI were greater than UMEC/VI only in patients with higher blood eosinophil counts together with either frequent moderate exacerbations or a severe exacerbation in the previous year.

Patients with a history of severe exacerbations in the previous year were more likely to have a severe exacerbation whilst on treatment than patients who only had moderate exacerbations. In the severe subgroup, FF/UMEC/VI was significantly more effective overall than FF/VI and UMEC/VI at reducing the rate of severe exacerbations.

In the subgroup who had a single moderate exacerbation in the previous year, the overall rate of exacerbations with UMEC/VI was lower than with FF/VI, although the difference was not statistically significant. When blood eosinophil counts were considered, there was a trend for patients on UMEC/VI to have higher rates of exacerbations compared with those on FF/VI at higher eosinophil counts, although the differences were not statistically significant, possibly because of lack of power owing to the small size of this subgroup. The patients in this subgroup are similar to those recruited to the FLAME study (NCT01782326), as approximately 80% had just one exacerbation in the year prior to the study. The effect of LAMA/LABA on exacerbation rates in these patients is in line with the FLAME study results.[22] Indeed, these findings comparing dual combinations in patients with one moderate exacerbation, coupled with the greater effect of ICS/LABA in patients with higher exacerbation risk, are compatible with the GOLD 2019 follow-up recommendations for the prevention of exacerbations. Greater
exacerbation risk along with higher blood eosinophil counts favour ICS/LABA rather than LAMA/LABA use.[1, 6]

The analysis shows differences in both the annual rate of exacerbations and the time-to-first exacerbation. The latter is important clinically because reducing exacerbation risk is an important goal for clinicians and patients. The effect on exacerbation rates reflects reductions in repeated exacerbations during the study and is likely to have contributed to the positive effects seen on health status.

Health status, as measured by SGRQ Total Score, did not show differential treatment effects by prior exacerbation history: FF/UMEC/VI was the most effective therapy and produced changes in health status greater than the MCID in all three subgroups. The greatest effect was seen in patients with frequent moderate but no severe exacerbations. UMEC/VI had similar effects to FF/VI.

The strengths of the analyses are the study population size, the prospective double-blinded study design comparing FF/UMEC/VI with FF/VI and UMEC/VI, the 52-week study duration, and the completeness and rigor of study endpoints collection.

Limitations include the retrospective nature of the subgroup classification and that entry criteria based on exacerbation frequency were confounded by percent predicted FEV1, mirroring GOLD recommendations at the time of study set-up. Therefore, patients with worse airflow obstruction had lower frequencies of historically reported moderate or severe exacerbations compared with those with less airflow limitation. Assessing treatment effects by prior exacerbation history subgroups gives insights into the relative effectiveness of ICS/LAMA/LABA, LAMA/LABA and ICS/LABA in these subgroups, but the interpretation of these results could be
confounded by additional factors such as blood eosinophil counts. The analysis by blood eosinophil counts relies on the statistical models fitted to this dataset but the thresholds we report for differential effects of therapy are similar to those reported in other studies comparing ICS/LAMA/LABA, ICS/LABA and LAMA/LABA.[7, 23]

In summary, these analyses show that FF/UMEC/VI was more effective than both FF/VI and UMEC/VI across multiple COPD endpoints. A more complex pattern was apparent for the comparison of FF/VI versus UMEC/VI that varied according to previous exacerbation history. The blood eosinophil count helps discriminate different treatment effects in patients at greater risk of exacerbations (i.e., the frequent moderate and severe subgroups) but had less influence in the single moderate subgroup. These results have relevance to clinical practice, as a higher exacerbation risk (based on previous history) and higher blood eosinophil counts favour the use of ICS/LAMA/LABA or ICS/LABA over LAMA/LABA.
Acknowledgements

Editorial support (in the form of writing assistance, assembling figures, collating author comments, grammatical editing and referencing) was provided by Chrystelle Rasamison and Rachel Edwards, at Fishawack Indicia Ltd, UK, and was funded by GSK. This study was funded by GSK (study number CTT116855). The funders of the study had a role in the study design, data analysis, data interpretation and writing of the report.

Conflict of interest

DMG Halpin has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis and Pfizer, and non-financial support from Boehringer Ingelheim and Novartis. MT Dransfield has received grant support from the Department of Defense, NIH and the American Lung Association; personal fees from AstraZeneca, Boehringer Ingelheim, PneumRx/BTG, Genentech, Quark Pharmaceuticals, Mereo and GSK; and contracted clinical trial support from Boehringer Ingelheim, Novartis, AstraZeneca, Yungjin, PneumRx/BTG, Pulmonx, Boston Scientific and GSK. MK Han has received personal fees from AstraZeneca, Boehringer Ingelheim and Mylan, and research support from Novartis and Sunovion. CE Jones, S Kilbride and DA Lipson are employees of GSK and hold stocks/shares in GSK. P Lange has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and GSK, and grant income from GSK. DA Lomas has received grant income, honoraria, and consultancy fees from GSK; and personal fees from Grifols; and chaired the GSK Respiratory Therapy Area Board 2012-2015. FJ Martinez has received personal fees and non-financial support from the American College of Chest Physicians, AstraZeneca, Boehringer Ingelheim, ConCert, Genentech, GSK, Inova Fairfax Health System, Miller Communications, National Society for Continuing Education, Novartis, Pearl Pharmaceuticals, PeerView Communications, Prime Communications, Puerto Rico Respiratory Society, Chiesi, Sunovion, Theravance, Potomac, University of Alabama Birmingham, Physicians
Education Resource, Canadian Respiratory Network, Teva and Dartmouth; non-financial support from ProterrixBio, Gilead, Nitto and Zambon; and personal fees from Columbia University, Integritas, MD magazine, Methodist Hospital Brooklyn, New York University, UpToDate, WebMD/MedScape, Western Connecticut Health Network, Patara/Respivant, PlatformIQ, American Thoracic Society, Rockpointe, Rare Disease Healthcare Communications and France Foundation; grant support from NIH; and is a member of steering committees for Afferent/Merck, Biogen, Veracyte, Prometic, Bayer, Bridge Biotherapeutics and ProMedior. S Pascoe was an employee of GSK at the time of the study and holds stocks/shares in GSK. D Singh has received personal fees from GSK, Cipla, Genentech and Peptinnovate; and personal fees and grant support from AstraZeneca, Boehringer Ingelheim, Chiesi, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Theravance and Verona. R Wise has received personal fees from AstraZeneca/MedImmune, Boehringer Ingelheim, Contrafect, Pulmonx, Roche, Spiration, Sunovion, Merck, Circassia, GSK, Pneuma, Verona, Bonti, Denali, Aradigm, Mylan/Theravance, Propeller Health and AbbVie; and grant support from AstraZeneca/MedImmune, Boehringer Ingelheim, Pearl Therapeutics, GSK and Sanofi-Aventis. GJ Criner has received personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, CSA Medical, Eolo, GSK, HGE Technologies, Novartis, Nuvaira, Olympus, Pulmonx, Verona and NGM Bio. Ellipta is owned by or licensed to the GSK Group of Companies.

**Contributions**

The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors, take responsibility for the integrity of the work as a whole, contributed to the writing and reviewing of the manuscript, and have given final approval for the version to be published. All authors had full access to the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
DMG Halpin, MT Dransfield and GJ Criner were involved in acquisition and analysis/interpretation of data. MK Han, CE Jones, S Kilbride, P Lange, DA Lomas, FJ Martinez, D Singh, and R Wise were involved in analysis/interpretation of data. S Pascoe and DA Lipson were involved in the conception/design of the study and analysis/interpretation of data.

Data sharing statement

Anonymised individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.
References
1. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, Lopez Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD Science Committee Report 2019. Eur Respir J 2019; 53.

2. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, Lopez Varela MV, Nishimura M, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017; 195: 557-582.

3. Han MK, Quibrera PM, Carretta EE, Barr RG, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL, Criner G, Dransfield MT, Hansel NN, Hoffman EA, Kanner RE, Krishnan JA, Martinez CH, Pirozzi CB, O'Neal WK, Rennard S, Tashkin DP, Wedzicha JA, Woodruff P, Paine R, 3rd, Martinez FJ, investigators S. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med 2017; 5: 619-626.

4. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA, Evaluation of CLtIPSEI. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.

5. Mullerova H, Maselli DJ, Locantore N, Vestbo J, Hurst JR, Wedzicha JA, Bakke P, Agusti A, Anzueto A. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest 2015; 147: 999-1007.

6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. http://goldcopd.org/gold-reports/. Updated 2019 18 January 2019.

7. Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fageras M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018; 6: 117-126.
8. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, Barnes NC. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 2016; 71: 118-125.

9. Roche N, Zysman M, Burgel PR. Blood eosinophil counts as a guide for COPD treatment strategies. Lancet Respir Med 2018; 6: 78-80.

10. Siddiqui SH, Pavord ID, Barnes NC, Guasconi A, Lettis S, Pascoe S, Petruzzelli S. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2018; 13: 3669-3676.

11. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ, Investigators I. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 2018; 378: 1671-1680.

12. Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, Dransfield MT, Pavord I, Barnes N. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J 2016; 48: 320-330.

13. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med 2019; 7: 745–756.

14. Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. Int J Chron Obstruct Pulmon Dis 2018; 13: 1125-1134.

15. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391: 1076-1084.

16. Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRIOLOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016; 388: 963-973.
17. Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017; 389: 1919-1929.

18. Calverley PMA, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EFM, Mezzanotte W, Disse B, Finnigan H, Asijee G, Hallmann C, Watz H. Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2017; 196: 1219-1221.

19. Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR. Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study. Am J Respir Crit Care Med 2018; 197: 1223-1226.

20. Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden BM, Polkey MI, Man WD. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med 2014; 2: 195-203.

21. Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD 2005; 2: 75-79.

22. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF, Investigators F. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016; 374: 2222-2234.

23. Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018; 6: 747-758.
**Table 1. Baseline demographics according to exacerbation history in the year prior to screening**

|                                | Single moderate subgroup | Frequent moderate subgroup | Severe subgroup |
|--------------------------------|--------------------------|----------------------------|----------------|
| **N=3056 (30%)**               |                          |                            |                |
| **Age (years), mean (SD)**     | 65.2 (7.95)              | 65.3 (8.46)                | 65.4 (8.29)    |
| **Sex (male), n (%)**          | 2069 (68)                | 2922 (63)                  | 1879 (70)      |
| **Race (white), n (%)**        | 2408 (79)                | 3604 (78)                  | 1971 (74)      |
| **Former smoker, n (%)**       | 1964 (64)                | 3014 (65)                  | 1790 (67)      |
| **BMI (kg/m^2), mean (SD)**    | 26.10 (6.043)            | 27.03 (5.833)              | 26.52 (6.532)  |
| **Lung function (post-bronchodilator)** |                          |                            |                |
| **At screening FEV₁ (L), mean (SD)** | 1.046 (0.3193)          | 1.437 (0.5036)             | 1.247 (0.5037) |
| **FEV₁ % predicted, mean (SD)** | 37.0 (8.85)             | 51.9 (14.77)               | 44.4 (15.25)   |
| **FEV₁/FVC ratio, mean (SD)**  | 0.421 (0.1028)           | 0.510 (0.1161)             | 0.458 (0.1201) |
| **Baseline* concomitant COPD medication at screening (alone or in combination), n (%)** |                          |                            |                |
| **LAMA**                       | 243 (8)                  | 375 (8)                    | 213 (8)        |
| **LABA**                       | 84 (3)                   | 166 (4)                    | 41 (2)         |
| **LAMA + LABA**                | 327 (11)                 | 392 (8)                    | 215 (8)        |
| **ICS + LABA**                 | 906 (30)                 | 1694 (37)                  | 741 (28)       |
| **ICS + LAMA + LABA**          | 1258 (41)                | 1651 (36)                  | 1274 (48)      |
| **Baseline blood eosinophil counts** |                        |                            |                |
| **Mean (SD)**                  | 203 (186)                | 230 (256)                  | 232 (242)      |
| **Percentage of patients with count:** |                        |                            |                |
| <100                           | 26%                      | 25%                        | 24%            |
| 100–300                        | 55%                      | 53%                        | 52%            |
| >300                           | 19%                      | 23%                        | 23%            |

*Between day of screening −3 days and date of screening (inclusive). BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; SD, standard deviation.
Table 2. Number of patients with ≥1 moderate, ≥1 severe and ≥1 moderate or severe on-treatment exacerbations during the study period by exacerbation history in the year prior to screening

| Exacerbation history subgroups: | Moderate only | Severe only |
|--------------------------------|--------------|-------------|
| **FF/UMEC/VI, n (%) rate [#]** |              |             |
| Single moderate subgroup       | 486 (41) 708.1 [750] | 112 (9) 121.8 [129] |
| Frequent moderate subgroup     | 797 (43) 805.4 [1368] | 117 (6) 77.7 [132] |
| Severe subgroup                | 436 (40) 783.7 [750] | 218 (20) 312.4 [299] |
| **FF/VI, n (%) rate [#]**      |              |             |
| Single moderate subgroup       | 542 (44) 857.8 [870] | 108 (9) 135.1 [137] |
| Frequent moderate subgroup     | 799 (44) 882.2 [1384] | 120 (7) 89.2 [140] |
| Severe subgroup                | 454 (42) 914.4 [800] | 233 (22) 348.6 [305] |
| **UMEC/VI, n (%) rate [#]**   |              |             |
| Single moderate subgroup       | 252 (41) 849.1 [429] | 55 (9) 120.7 [61] |
| Frequent moderate subgroup     | 430 (46) 1002.1 [790] | 96 (10) 145.9 [115] |
| Severe subgroup                | 205 (40) 958.8 [388] | 121 (23) 410.2 [166] |

The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). Data are reported as number of patients (%), and rate (number of events). Rate is reported per 1000 subject-years, calculated as the number of events x 1000, divided by the total duration at risk. 

#, number of events; COPD, chronic obstructive pulmonary disease; FF, fluticasone furoate; UMEC, umeclidinium; VI, vilanterol. Figure legends

Figure 1. Number of combined moderate or severe COPD exacerbations per patient by prior exacerbation subgroup

The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). COPD, chronic obstructive pulmonary disease; FF, fluticasone furoate; UMEC, umeclidinium; VI, vilanterol.
**Figure 2.** Annual rate of on-treatment (A) moderate or severe and (B) severe exacerbations according to exacerbation history in the year prior to screening for each treatment comparison

The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). *Post hoc analysis. CI, confidence interval; COPD, chronic obstructive pulmonary disease; FF, fluticasone furoate; RR, rate ratio; UMEC, umeclidinium; VI, vilanterol.

**Figure 3.** Time-to-first combined (A) moderate or severe and (B) severe COPD exacerbation by treatment by prior exacerbation subgroup for each treatment comparison

The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). Post hoc analysis. CI, confidence interval; COPD, chronic obstructive pulmonary disease; FF, fluticasone furoate; HR, hazard ratio; UMEC, umeclidinium; VI, vilanterol.

**Figure 4.** Annual rate of moderate or severe exacerbations, by baseline blood eosinophil count and individual treatment group by prior exacerbation subgroup: (A) single moderate, (B) frequent moderate, (C) severe

The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). FF, fluticasone furoate; UMEC, umeclidinium; VI, vilanterol.
Figure 5. Between-treatment differences (FF/UMEC/VI vs UMEC/VI and FF/VI vs UMEC/VI) in rates of moderate or severe exacerbations, by baseline blood eosinophil count and prior exacerbation subgroup: (A) single moderate, (B) frequent moderate, (C) severe.

The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). FF, fluticasone furoate; UMEC, umeclidinium; VI, vilanterol.

Figure 6. LS mean (95% CI) change in SGRQ at Week 52 by prior exacerbation subgroup

The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). Post hoc analysis. Numbers below the brackets indicate the between-treatment difference (95% CI) in LS mean change from baseline at Week 52 in SGRQ Total Score for FF/UMEC/VI vs UMEC/VI, FF/UMEC/VI vs FF/VI and UMEC/VI vs FF/VI. *p<0.05. CI, confidence interval; FF, fluticasone furoate; LS, least squares; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol.
Patients (%)

Total on-treatment moderate/severe exacerbations per patient:

- FF/UMEC/VI
- FF/VI
- UMEC/VI

0 1 2  ≥3

Single moderate subgroup

Frequent moderate subgroup

Severe subgroup
## A

| Comparison                  | Subgroup                       | Treatment A (Model estimated annual rate, 95% CI) | Treatment B (Model estimated annual rate, 95% CI) | RR (95% CI) | p-value |
|-----------------------------|--------------------------------|-----------------------------------------------|-----------------------------------------------|-------------|---------|
| **FF/UMEC/VI vs FF/VI**     | Single moderate subgroup       | 0.85 (0.78, 0.92)                             | 1.06 (0.97, 1.15)                             | 0.80 (0.71, 0.90) | <0.001  |
|                             | Frequent moderate subgroup     | 0.85 (0.80, 0.91)                             | 0.96 (0.90, 1.03)                             | 0.89 (0.81, 0.98) | 0.016   |
|                             | Severe subgroup                | 1.06 (0.98, 1.16)                             | 1.28 (1.18, 1.39)                             | 0.83 (0.74, 0.93) | 0.002   |
| **FF/UMEC/VI vs UMEC/VI**   | Single moderate subgroup       | 0.85 (0.78, 0.92)                             | 1.03 (0.92, 1.16)                             | 0.82 (0.71, 0.95) | 0.007   |
|                             | Frequent moderate subgroup     | 0.85 (0.80, 0.91)                             | 1.21 (1.10, 1.32)                             | 0.71 (0.63, 0.79) | <0.001  |
|                             | Severe subgroup                | 1.06 (0.98, 1.16)                             | 1.43 (1.27, 1.61)                             | 0.74 (0.65, 0.86) | <0.001  |
| **UMEC/VI vs FF/VI**        | Single moderate subgroup       | 1.03 (0.92, 1.16)                             | 1.06 (0.97, 1.15)                             | 0.98 (0.85, 1.13) | 0.782   |
|                             | Frequent moderate subgroup     | 1.21 (1.10, 1.32)                             | 0.96 (0.90, 1.03)                             | 1.26 (1.12, 1.41) | <0.001  |
|                             | Severe subgroup                | 1.43 (1.27, 1.61)                             | 1.28 (1.18, 1.39)                             | 1.12 (0.97, 1.29) | 0.129   |

## B*

| Comparison                  | Subgroup                       | Treatment A (Model estimated annual rate, 95% CI) | Treatment B (Model estimated annual rate, 95% CI) | RR (95% CI) | p-value |
|-----------------------------|--------------------------------|-----------------------------------------------|-----------------------------------------------|-------------|---------|
| **FF/UMEC/VI vs FF/VI**     | Single moderate subgroup       | 0.11 (0.09, 0.14)                             | 0.13 (0.10, 0.16)                             | 0.88 (0.66, 1.18) | 0.388   |
|                             | Frequent moderate subgroup     | 0.06 (0.05, 0.08)                             | 0.07 (0.06, 0.09)                             | 0.84 (0.64, 1.10) | 0.198   |
|                             | Severe subgroup                | 0.29 (0.25, 0.33)                             | 0.33 (0.28, 0.38)                             | 0.88 (0.72, 1.08) | 0.226   |
| **FF/UMEC/VI vs UMEC/VI**   | Single moderate subgroup       | 0.11 (0.09, 0.14)                             | 0.11 (0.08, 0.15)                             | 0.99 (0.69, 1.43) | 0.962   |
|                             | Frequent moderate subgroup     | 0.06 (0.05, 0.08)                             | 0.14 (0.11, 0.17)                             | 0.45 (0.33, 0.61) | <0.001  |
|                             | Severe subgroup                | 0.29 (0.25, 0.33)                             | 0.42 (0.34, 0.51)                             | 0.69 (0.54, 0.88) | 0.003   |
| **UMEC/VI vs FF/VI**        | Single moderate subgroup       | 0.11 (0.08, 0.15)                             | 0.13 (0.10, 0.16)                             | 0.89 (0.62, 1.28) | 0.519   |
|                             | Frequent moderate subgroup     | 0.14 (0.11, 0.17)                             | 0.07 (0.06, 0.09)                             | 1.86 (1.37, 2.51) | <0.001  |
|                             | Severe subgroup                | 0.42 (0.34, 0.51)                             | 0.33 (0.28, 0.38)                             | 1.28 (1.00, 1.64) | 0.048   |
A

| Patients with event, n/N (%) | HR (95% CI) | p-value |
|-----------------------------|-------------|---------|
| **FF/UMEC/VI vs FF/VI**     |             |         |
| Single moderate subgroup    | 0.81 (0.72, 0.91) | <0.001  |
| Frequent moderate subgroup  | 0.92 (0.83, 1.01) | 0.069   |
| Severe subgroup             | 0.81 (0.72, 0.91) | <0.001  |
| **FF/UMEC/VI vs UMEC/VI**   |             |         |
| Single moderate subgroup    | 0.92 (0.79, 1.06) | 0.246   |
| Frequent moderate subgroup  | 0.80 (0.72, 0.90) | <0.001  |
| Severe subgroup             | 0.81 (0.70, 0.93) | 0.003   |
| **UMEC/VI vs FF/VI**        |             |         |
| Single moderate subgroup    | 0.88 (0.76, 1.02) | 0.080   |
| Frequent moderate subgroup  | 1.14 (1.02, 1.27) | 0.023   |
| Severe subgroup             | 1.00 (0.87, 1.15) | 0.991   |

B

| Patients with event, n/N (%) | HR (95% CI) | p-value |
|-----------------------------|-------------|---------|
| **FF/UMEC/VI vs FF/VI**     |             |         |
| Single moderate subgroup    | 0.99 (0.76, 1.28) | 0.914   |
| Frequent moderate subgroup  | 0.88 (0.69, 1.14) | 0.347   |
| Severe subgroup             | 0.83 (0.69, 1.00) | 0.050   |
| **FF/UMEC/VI vs UMEC/VI**   |             |         |
| Single moderate subgroup    | 1.00 (0.72, 1.38) | 0.978   |
| Frequent moderate subgroup  | 0.55 (0.42, 0.72) | <0.001  |
| Severe subgroup             | 0.77 (0.62, 0.96) | 0.021   |
| **UMEC/VI vs FF/VI**        |             |         |
| Single moderate subgroup    | 0.99 (0.72, 1.37) | 0.952   |
| Frequent moderate subgroup  | 1.62 (1.24, 2.12) | <0.001  |
| Severe subgroup             | 1.08 (0.87, 1.34) | 0.498   |
LS mean (95% CI) change from baseline in SGRQ total score

**Single moderate subgroup**
- FF/UMEC/VI: -4.8 (-2.0, 0.8)
- FF/VI: -2.4 (-3.0)
- UMEC/VI: -3.0

**Frequent moderate subgroup**
- FF/UMEC/VI: -6.3
- FF/VI: -4.9 (-2.4, -0.4)*
- UMEC/VI: -4.5

**Severe subgroup**
- FF/UMEC/VI: -4.6
- FF/VI: -2.9 (-3.0)
- UMEC/VI: -3.0

* indicates statistical significance.
Proportion of responders:

SGRQ total score at week 52 (%)

|        | FF/UMEC/VI | FF/VI | UMEC/VI |
|--------|------------|-------|---------|
| Single moderate subgroup | 1.29 (1.05, 1.59)* | 1.54 (1.30, 1.83)* | 1.19 (0.97, 1.48) |
| Frequent moderate subgroup | 1.43 (1.22, 1.69)* | 1.36 (1.19, 1.55)* | 0.95 (0.80, 1.12) |
| Severe subgroup | 1.52 (1.21, 1.91)* | 1.38 (1.15, 1.64)* | 0.90 (0.72, 1.14) |

Proportion of responders: SGRQ total score at week 52 (%)
LS mean (95% CI) change from baseline in trough FEV₁ (mL)

- Single moderate subgroup
  - FF/UMEC/VI: 30 (5, 54)*
  - FF/VI: 93 (73, 113)*
  - UMEC/VI: 63 (38, 88)*

- Frequent moderate subgroup
  - FF/UMEC/VI: 67 (44, 91)*
  - FF/VI: 95 (76, 113)*
  - UMEC/VI: 27 (4, 51)*

- Severe subgroup
  - FF/UMEC/VI: 56 (26, 85)*
  - FF/VI: 102 (79, 125)*
  - UMEC/VI: 46 (17, 76)*

---

* Statistically significant difference from baseline.